Papanastasiou, Philemon

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet

Bone health and osteoporosis researchBone health and treatments

Cited by 527

Fracture risk and zoledronic acid therapy in men with osteoporosis

Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine

Bone health and osteoporosis researchBone health and treatments

Cited by 359

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids

Devogelaer, J.-P., Sambrook, P., Reid, D. M., Goemaere, S., Ish-Shalom, S., Collette, J., Su, G., Bucci-Rechtweg, C., Papanastasiou, P., & Reginster, J.-Y. (2013) · Rheumatology

Bone health and osteoporosis researchBone health and treatments

Cited by 19